Virax Biolabs up on emergency use authorization for COVID-19 Rapid Antigen Test
06/12/2022 13:54
** Shares of Virax Biolabs Group Ltd VRAX.O rise 4.3% to
$1.43 before the bell
** U.S. FDA grants Emergency Use Authorization for VRAX's
over-the-counter COVID-19 Rapid Antigen Test urn:newsml:reuters.com:*:nPn3RjnQda
** We have significant manufacturing capacity of up 2 mln
tests per day which will allow us to serve a large portion of
the US market, if necessary - CEO James Foster
** Up to Monday's close, stock had fallen ~92% since market
debut in July 2022
(Reporting by Khushi Mandowara)
((Khushi.Mandowara@thomsonreuters.com;))